Optimizing the use of NGS in pts with urothelial carcinoma: recommendations by the 2023 Ospedale San Raffaele Retreat panel Petros Grivas Valentina Tateo Chiara Mercinelli Antonio Cigliola Neeraj Agarwal, MD, FASCO Ashish M. Kamat, MD, MBBS Lars Dyrskjøt ylt Shilpa Gupta Philippe spiess Marco Moschini clinical-genitourinary-cancer.com/article/S1558-…

“[The] NURE-Combo trial provided insights into the potential value of expanding chemotherapy combinations with immune checkpoint [inhibitors] in muscle-invasive disease," said Chiara Mercinelli, MD. #AUA24 | Amer. Urol. Assn. Chiara Mercinelli cancernetwork.com/view/nivolumab…

Profoundly honored to serve as new Associate Editor ⁦Journal of Clinical Oncology⁩ continuing the path of Mike Carducci | a special thank to the EiC ⁦Jonathan Friedberg⁩ and the exceptional editorial staff ⁦ASCO⁩ ⁦Università Vita-Salute San Raffaele⁩ ⁦⁦Ospedale San Raffaele⁩ ascopubs.org/jco/about/edit…

Our latest collaboration on penile SCC finally out 💪 Majd Al Assaad, MD Houssein Safa, MD Andrea Necchi Philippe spiess jc Global Society of Rare GU Tumors Urologic Clinics Università Vita-Salute San Raffaele

Updated state-of-the-art in treatment of penile SCC - Andrea Necchi Chiara Mercinelli jc Philippe spiess Global Society of Rare GU Tumors UroToday.com oncodaily.com/68285.html #Cancer #GlobalSocietyOfRareGU #OncoDaily #Oncology #SCC #UroToday

Super Martina Catalano 🔥

Here we go with our Università Vita-Salute San Raffaele medical student Giovanni Pastorino presenting #NureCombo neoadj trial biomarker data. Congratulations the future is bright! Ospedale San Raffaele Chiara Mercinelli Antonio Cigliola Valentina Tateo ASCO #ASCO24 UroToday.com

Immensely proud of the excellent work made by our brilliant #medstusent Giovanni Pastorino 💪 Università Vita-Salute San Raffaele ASCO #ASCO24

The spectrum of cutaneous toxicities related to novel GU cancer therapies | by our medical student Rachel Daher Philippe spiess Petros Grivas Chiara Mercinelli Valentina Tateo Antonio Cigliola Ashish M. Kamat, MD, MBBS Shilpa Gupta Critical Reviews in Oncology Hematology (CROH) Università Vita-Salute San Raffaele Ospedale San Raffaele sciencedirect.com/science/articl…

I am happy to share the preliminary programme of Ospedale San Raffaele #GURetreat24 3rd edition. Featuring the advances made in the field in 2024, presented by global KOL. Do not miss the opportunity to register at expopoint.it Università Vita-Salute San Raffaele Global Society of Rare GU Tumors ESMO - Eur. Oncology UroToday.com European Association of Urology (EAU)

IDO1 inhibition was ineffective in UC. Pembrolizumab+epacadostat/placebo for cis-ineligible mUC: ECHO-307/KEYNOTE-672 study | BMC Cancer | also negatively tested in neoadjuvant setting #Optimus ⁦Petros Grivas⁩ ⁦Michiel van der Heijden⁩ #Ronald deWit bmccancer.biomedcentral.com/articles/10.11…

Urachal and Nonurachal Adenocarcinomas of the Urinary Bladder: A Comprehensive Genomic Profiling Study | JCO Precision Oncology ASCO | Antonio Cigliola Chiara Mercinelli Valentina Tateo Brigida Maiorano Università Vita-Salute San Raffaele Ospedale San Raffaele UroToday.com Medscape Foundation Medicine Petros Grivas Ashish M. Kamat, MD, MBBS

Out in Journal of Clinical Oncology our next piece of the neoadjuvant puzzle in muscle-invasive #bladdercancer. Taxanes could be another good choice of backbone chemo to combine with IO, overcoming the known limits of platinum. #NureCombo provided Nivo/ABX x4 > RC > adj Nivo x13. N=31. 22 pts

Finally, educational and growing career path of neoadjuvant platform continued. Commitment of pts and families, first author resident Chiara Mercinelli And the outstanding team made this idea possible Valentina Tateo Antonio Cigliola Brigida Maiorano miriam borella Gaia Latini

The NURE-Combo trial shows promising results with a combination of nivolumab & nab-paclitaxel as neoadjuvant therapy, achieving 32.3% pathologic complete response & 70.9% major pathologic response rates. #oncology #cancer #immunotherapy Andrea Necchi OncoAlert Alberto Briganti

Finally out!! Neoadjuvant Nivo + ABX with 35.7% pCR and nearly 70% pMR in MIBC regardless of platinum eligibility. Lower PB fraction of PMN-MDSCs and intermediate monocyte in pCR but at baseline only. CD11b+CD33hi monos increase from baseline to C2D1. Next step: SG +/- Pembro

What’s on the horizon for metastatic #ProstateCancer patients? Looking forward to this informative session, Saturday at #ESMO24. Presentations from Misha Beltran, Neeraj Agarwal, MD, FASCO, Wilbert Zwart, and Juliet Carmichael, and more! Written coverage to follow on UroToday! ESMO - Eur. Oncology

What a great #ESMO24 start today with Elena Castro silke gillessen in a very stimulating session on treatment beyond #ARPI in #prostatecancer ESMO - Eur. Oncology